Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Leases (2016 - 2018)

Amphastar Pharmaceuticals has reported Capital Leases over the past 6 years, most recently at $1.1 million for Q4 2018.

  • Quarterly results put Capital Leases at $1.1 million for Q4 2018, down 22.25% from a year ago — trailing twelve months through Dec 2018 was $1.1 million (down 22.25% YoY), and the annual figure for FY2018 was $1.1 million, down 22.25%.
  • Capital Leases for Q4 2018 was $1.1 million at Amphastar Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over the last five years, Capital Leases for AMPH hit a ceiling of $1.9 million in Q2 2016 and a floor of $802000.0 in Q4 2015.
  • Median Capital Leases over the past 5 years was $1.2 million (2018), compared with a mean of $1.3 million.
  • Biggest five-year swings in Capital Leases: skyrocketed 101.25% in 2016 and later decreased 22.25% in 2018.
  • Amphastar Pharmaceuticals' Capital Leases stood at $1.0 million in 2014, then dropped by 21.53% to $802000.0 in 2015, then surged by 101.25% to $1.6 million in 2016, then fell by 15.92% to $1.4 million in 2017, then decreased by 22.25% to $1.1 million in 2018.
  • The last three reported values for Capital Leases were $1.1 million (Q4 2018), $1.1 million (Q3 2018), and $1.2 million (Q2 2018) per Business Quant data.